Vanguard Group
BBNX

Vanguard Group’s Beta Bionics BBNX Stock Holding History

Vanguard Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$67.6M Buy
2,218,238
+2,053
+0.1% +$54.8K ﹤0.01% 2012
2025
Q3 		$44M Buy
2,216,185
+1,509,217
+213% +$26.5M ﹤0.01% 2214
2025
Q2 		$10.3M Sell
706,968
-2,287
-0.3% -$32.4K ﹤0.01% 2882
2025
Q1 		$8.68M Buy
+709,255
New +$13.2M ﹤0.01% 2920

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group's BBNX Position: Q4 2025 in Review

Vanguard Group increased its Beta Bionics (BBNX) stake by 0.09% in Q4 2025, buying an estimated $54.8K and bringing the position to 2,218,238 shares worth $67.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Vanguard Group first reported a position in BBNX in Q1 2025 and has held it in 4 quarters since. 158 funds tracked by Wall St. Rank hold BBNX as of Q4 2025.

  • Vanguard Group held 2,218,238 shares of Beta Bionics worth $67.6M as of Q4 2025.
  • Vanguard Group bought 2,053 Beta Bionics shares in Q4 2025, an estimated $54.8K.
  • Beta Bionics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2012 holding.
  • Vanguard Group first reported a position in Beta Bionics in Q1 2025 and has held it in 4 quarters since.
  • 158 funds tracked by Wall St. Rank held Beta Bionics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.